Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Dean F. Bajorin, Padmanee Sharma, David I. Quinn, Elizabeth R. Plimack, Jean H. Hoffman-Censits, Peter H. O'Donnell, Arlene O. Siefker-Radtke, Nadeem Anwar Sheikh, Jennifer Susan LIll, James B. Trager, Leonard G. Gomella | ||||||||||||
Title | Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts). | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/162594-176 | ||||||||||||
Abstract Text | J Clin Oncol 34, 2016 (suppl; abstr 4513) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
lapuleucel-T | lapuleucel-T | 0 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
lapuleucel-T | Neuvenge|APC8024|DN24-02 | Neuvenge (lapuleucel-T) is a cellular vaccine of antigen-presenting cells cultured with recombinant Erbb2 (Her2) antigen linked to GMCSF, which stimulates anti-tumor response against Erbb2 (Her2) expressing tumor cells (J Clin Oncol 34, 2016 (suppl; abstr 4513), PMID: 19723649). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|